Allergan, Inc. is aiming to push the use of Botox (onabotulinumtoxinA) into more medical indications, and next up is the treatment of patients with idiopathic overactive bladder who are not managed on anticholinergic treatment.
During an R&D day presentation March 28, management overviewed top-line data from two Phase III clinical trials in overactive bladder (OAB) and announced the submission of regulatory filings for the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?